Clinical Trial Info

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

Authored by

This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo.

The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29.